UK medicines regulation disincentivising investment in research development, finds survey

The Association of the British Pharmaceutical Industry’s survey results accompany 12 recommendations for improving the Medicines and Healthcare Products Regulatory Agency’s effectiveness as a UK medicines regulator.
Several medicine packets in a pile

The majority of pharmaceutical manufacturers responding to a survey have said the UK’s medicines regulatory environment has an ‘unfavourable’ impact on their decision to invest in research development.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated